The current COVID-19 pandemic illustrates how vulnerable the world is to viral infections. There is a strategic need for new approaches to treat patients exposed to viruses without creating drug resistance and protect high-risk patients. A new class of antiviral drugs is needed to change the paradigm from having “one drug against one virus” to “one drug against multiple viruses.
Our mission is to develop and commercialize our small molecule platform of broad-spectrum antiviral drugs to overcome the clinical challenge of current and future viral infections via a single mechanism rather than the current piecemeal approach to individual viruses.
Our preclinical drug candidates, block the replication of important viruses with unmet clinical needs- Herpes, HIV, adenovirus, coronaviruses, influenza virus, and other known and new emerging viruses. They modulate RNA processing and are highly effective against SARS-CoV2 and common circulating coronaviruses. The multiple emerging COVID-19 variants, which pose a risk for vaccine failure, require RNA processing and therefore, will retain the sensitivity to our drugs.
Company Details
- Employees
- 4
- Founded
- -
- Address
- 1 Yonge St, Suite 1801,canada
- ma****@****arb.com
- Industry
- Biotechnology
- Website
- virocarb.com
- Keywords
- Terrain Life Science.
- HQ
- Toronto , Ontario
Virocarb Inc. Questions
Virocarb Inc.'s website is virocarb.com
Virocarb Inc.'s LinkedIn profile is https://ca.linkedin.com/company/virocarb-inc-
Virocarb Inc. has
4 employees.
View email and phone details for 4
employees at Virocarb Inc..
Virocarb Inc.'s industry is
Biotechnology
Virocarb Inc.'s top competitors are
Bough Biosciences,
Boston Biopharma Consultants,
Mediphage,
Aperture Bio,
Virica Biotech,
Genebio Systems, Inc.,
Terrain Life Science,
Vivo Surgery,
Aveta Biomics Inc,
Prana Biosciences Inc..
Virocarb Inc.'s support email address is mario.huesca@virocarb.com
Virocarb Inc.'s categories are Biotechnology
Virocarb Inc.'s founding year is 2011
